How the smartest pharmaceutical IP teams build exclusivity that outlasts the molecule by a decade — and what happens when […]

There is a class of pharmaceutical asset that rarely shows up in earnings calls but drives billions in brand revenue

Somewhere in a brand-name drug company’s lifecycle management plan, there is usually a line item that reads something like: ‘Evaluate

The FDA Orange Book publishes patent expiry dates. Analysts read them, model them into revenue forecasts, and brief executives on

How to turn a single FDA regulatory date into a structured, repeatable, competitively timed sales funnel for active pharmaceutical ingredient

When a pharmaceutical brand launches an authorized generic, the press release typically says something about “patient access” or “expanding options.”

When a blockbuster drug loses patent protection, the resulting price war follows a predictable arc — but the speed, depth,

From Paragraph IV certifications to 30-month stays, Orange Book listings to authorized generics — a practitioner’s guide to the law

Pharmaceutical pipeline valuations collapse fastest not at clinical failure, but at patent expiry. The day a branded generic crosses the